BBT-401

N/A

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NameBBT-401
Drug Alias NameBBT-401BBT-401-1S
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionE3 ubiquitin-protein ligase pellino homolog 1 inhibitors
TargetsE3 ubiquitin-protein ligase pellino homolog 1
Therapy Area/IndicationsColitis, Ulcerative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUkrainePoland +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesKorea Research Institute Of Chemical TechnologySungkyunkwan University
China Registration ClassN/A

Develop Information

Active CompaniesBridge Biotherapeutics IncBiliji Biotechnology Co Ltd
Inactive CompaniesCorealis Pharma IncBeijing Jingcheng Yongtai Pharmaceutical Technology Co Ltd
Active IndicationsColitis, Ulcerative
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A